Aleksandra Ciepłucha

Aleksandra Ciepłucha

Auto-generated profile, based on publicly available information

Aleksandra Ciepłucha

1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2020 in Current Cardiology Reports
Verified
Journal Article
Open access
PDF file
DKDaria M. Keller
Daria M. Keller
MOMary-Tiffany Oduah
Mary-Tiffany Oduah
TKThomas Kiebalo
Thomas Kiebalo
SNSonia Nartowicz
Sonia Nartowicz
MBMarcin Bęben
Marcin Bęben
ESEwa Straburzyńska-Migaj
Ewa Straburzyńska-Migaj
Purpose of Review: Heart failure with preserved ejection fraction (HFpEF) is a relatively new disease entity used in medical terminology; however, both the number of patients and its clinical significance are growing. HFpEF used to be seen as a mild condition; however, the symptoms and quality of life of the patients are comparable to those with reduced ejection fraction. The disease is much more complex than previously thought. In this article, information surrounding the etiology, diagnosis, prognosis, and possible therapeutic options of HFpEF are reviewed and summarized. Recent Findings: It has recently been proposed that heart failure (HF) is rather a heterogeneous syndrome with a spectrum of overlapping and distinct characteristics. HFpEF itself can be distilled into different phenotypes based on the underlying biology. The etiological factors of HFpEF are unclear; however, systemic low-grade inflammation and microvascular damage as a consequence of comorbidities associated with endothelial dysfunction, oxidative stress, myocardial remodeling, and fibrosis are considered to play a crucial role in the pathogenesis of a disease. The H2FPEF score and the HFpEF nomogram are recently validated highly sensitive tools employed for risk assessment of subclinical heart failure. Summary: Despite numerous studies, there is still no evidence-based pharmacotherapy for HFpEF and the mortality and morbidity associated with HFpEF remain high. A better understanding of the etiological factors, the impact of comorbidities, the phenotypes of the disease, and implementation of machine learning algorithms may play a key role in the development of future therapeutic strategies.

13 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Sylwia Sławek-SzmytSylwia Sławek-Szmyt
Sylwia Sławek-Szmyt
KKKatarzyna Kawka-Paciorkowska
Katarzyna Kawka-Paciorkowska
ACAleksandra Ciepłucha
Aleksandra Ciepłucha
MLMaciej Lesiak
Maciej Lesiak
MRMariola Ropacka-Lesiak
Mariola Ropacka-Lesiak
Cardiovascular diseases (CVDs) remain the leading cause of death in women worldwide. Although traditional risk factors increase later-life CVD, pregnancy-associated complications additionally influence future CVD risk in women. Adverse pregnancy outcomes, including preeclampsia and fetal growth restriction (FGR), are interrelated disorders caused by placental dysfunction, maternal cardiovascular maladaptation to pregnancy, and maternal abnormalities such as endothelial dysfunction, inflammation, hypercoagulability, and vasospasm. The pathophysiologic pathways of some pregnancy complications and CVDs might be linked. This review aimed to highlight the associations between specific adverse pregnancy outcomes and future CVD and emphasize the importance of considering pregnancy history in assessing a woman’s CVD risk. Moreover, we wanted to underline the role of maternal cardiovascular maladaptation in the development of specific pregnancy complications such as FGR.

21 February 2018 in Heart and Vessels
Verified
Journal Article
Open access
PDF file
ACAleksandra Ciepłucha
Aleksandra Ciepłucha
OTOlga Trojnarska
Olga Trojnarska
AKAnna Kociemba
Anna Kociemba
MŁMagdalena Łanocha
Magdalena Łanocha
MBMikolaj Barczynski
Mikolaj Barczynski
MPMalgorzata Pyda
Malgorzata Pyda
Heart failure and arrhythmia are common complications in adults with Ebstein’s anomaly. They may result not only from hemodynamic alterations, but also from myocardial fibrosis. Late gadolinium enhancement (LGE) by CMR enables the evaluation of myocardial fibrosis. The aim of the study was to asses the presence of LGE and its relation to clinical outcome. We studied a group of 37 unoperated adults aged 43.0 ± 14.4 years with Ebstein’s anomaly from the congenital heart disease outpatient clinic. Study protocol included: cardiopulmonary test, assessment of supraventricular arrhythmia (SVA), and CMR with evaluation of cardiac chambers’ morphology and function, and presence of LGE. Variables following normal distribution were shown as mean ± SD if otherwise median (range) was applied. Fibrosis was found in 18 patients (48.6%) and was distributed as follows: 12 patients (32.4%) in the right atrium, 12 (32.4%) in the atrialized right ventricle, and 2 (5.4%) in the functional right ventricle. In patients with fibrosis, the tricuspid regurgitation fraction was bigger (48.3 ± 19.7 vs. 36.1 ± 22.6%, p = 0.048) and SVA was more frequent [12 (66.7%) vs. 6 (31.6%), p = 0.046] when compared to patients without fibrosis. However, exercise capacity did not differ between patients with and without LGE (peak VO2 24.0 ± 4.7 vs. 23.7 ± 4.4, p = 0.87). In adults with Ebstein’s anomaly fibrosis estimated by LGE-CMR was localized in the right atrium and the right ventricle only. Volume overload resulting from tricuspid regurgitation might be a factor conducive to fibrosis. Myocardial fibrosis did not influence exercise capacity. Association between myocardial fibrosis and supraventricular arrhythmia was confirmed.

18 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ABAgnieszka Bartczak-Rutkowska
Agnieszka Bartczak-Rutkowska
LTLidia Tomkiewicz-Pająk
Lidia Tomkiewicz-Pająk
KKKatarzyna Kawka-Paciorkowska
Katarzyna Kawka-Paciorkowska
NBNatalia Bajorek
Natalia Bajorek
ACAleksandra Ciepłucha
Aleksandra Ciepłucha
OTOlga Trojnarska
Olga Trojnarska
Women with single ventricle physiology after the Fontan procedure, despite numerous possible complications, can reach adulthood and give birth. Pregnancy poses a hemodynamic burden for distorted physiology of Fontan circulation, but according to the literature, it is usually well tolerated unless the patient is a “failing” Fontan. Our study aimed to assess maternal and fetal outcomes in patients after the Fontan procedure followed up in two tertiary Polish medical centers. We retrospectively evaluated all pregnancies in women after the Fontan procedure who were followed up between 1995–2022. During the study period, 15 women after the Fontan procedure had 26 pregnancies. Among 26 pregnancies, eleven ended with miscarriages, and 15 pregnancies resulted in 16 live births. Fetal complications were observed in 9 (56.3%) live births, with prematurity being the most common complication (n = 7, 43.8%). We recorded 3 (18.8%) neonatal deaths. Obstetrical complications were present in 6 (40%) out of 15 completed pregnancies—two (13.3%) cases of abruptio placentae, two (13.3%) pregnancies with premature rupture of membranes, and two (13.3%) patients with antepartum hemorrhage. There was neither maternal death nor heart failure decompensation during pregnancy. In two (13.3%) women, atrial arrhythmia developed. One (6.7%) patient in the second trimester developed ventricular arrhythmia. None of the patients suffered from systemic thromboembolism during pregnancy. Pregnancy in women after the Fontan procedure is well tolerated. However, it is burdened by a high risk of miscarriage and multiple obstetrical complications. These women require specialized care provided by both experienced cardiologists and obstetricians.

1 July 2012 in International Journal of Cardiology
Verified
Journal Article
Closed access
Katarzyna Mizia-StecKatarzyna Mizia-Stec
Katarzyna Mizia-Stec
OTOlga Trojnarska
Olga Trojnarska
LSLudwina Szczepaniak-Chicheł
Ludwina Szczepaniak-Chicheł
MGMarcin Gabriel
Marcin Gabriel
ABAgnieszka Bartczak-Rutkowska
Agnieszka Bartczak-Rutkowska
ZGZbigniew Gąsior
Zbigniew Gąsior

1 December 2019 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
ACAleksandra Cieplucha
Aleksandra Cieplucha
OTOlga Trojnarska
Olga Trojnarska
ABAgnieszka Bartczak-Rutkowska
Agnieszka Bartczak-Rutkowska
AKAnna Kociemba
Anna Kociemba
JRJustyna Rajewska-Tabor
Justyna Rajewska-Tabor
MPMałgorzta Pyda
Małgorzta Pyda